Di seguito sono riportate le informazioni acquisite su BIOGEN INC., che non è ancora inclusa nel nostro perimetro di ricerca.

Per richiedere una valutazione di questa azienda e l'inserimento nel Ranking OpenCorporation o se hai dati ulteriori, diversi e più aggiornati di quanto pubblicato in questa scheda aziendale OpenCorporation, scrivi a info@opencorporation.org così che il nostro team possa tenerne conto.

Aggiornato il 31 marzo 2022

Descrizione attività
(disponibile solo in inglese)

Manufacture of pharmaceutical preparations (NACE2 2120)

The company is primarily engaged in the development, manufacture and commercialization of therapies in the areas of oncology, neurology and immunology. It is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from the company's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. The company was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. Its headquarters is located in Cambridge, Massachusetts.The company's capabilities and capacity for protein manufacturing are world-class in quality and scale. It has expertise in protein expression in mammalian cells and process sciences capability for cell culture and downstream processing. It is one of a few biotechnology companies with three licensed and dedicated biological bulk-manufacturing facilities. These facilities include a 250,000-square-foot large-scale manufacturing (LSM) plant in Research Triangle Park (RTP), North Carolina. The LSM has 90,000 liters of bioreactor capacity and is one of the largest biologic manufacturing facilities of its kind in the world.The company also operates other licensed manufacturing facilities in RTP and Cambridge, Massachusetts and has one of the leading capacities for biologics manufacturing in the biotechnology industry. In addition, the company is building another 90,000-liter, world-class manufacturing facility located in Hillerod, Denmark. The company is one of the world's largest biotechnology companies, with an R&D budget that exceeds 750 million. The company maintains research centers of excellence in San Diego, California and Cambridge, Massachusetts.The company's products are categorized into five areas. The first area is Oncology, which include RITUXAN, ZEVALIN, Anit-CD80 mAb, Anti-CD23 mAb, M200, HSP90 Inhibitor, Anti-Cripto mAb, Anti-BR3 mAb, and Anti_IGF-1R. Under the Neurology area, products include AVONEX, TYSABRI, BG-12, RITUXAN, Daclizumab, CDP323, BIIB014/V2006, Neublastin, LINGO, and Nogo. The next area, Immunology, includes RITUXAN, FUMADERM, TYSABRI, Humanized Anti-CD20 mAb, Soluble Lymphotoxin Beta Receptro, Soluble BAFF Antagonist, Anti-CD40L, and Anti-TWEAK. The Cardiopulmonary area includes products such as Lixivaptan, ADENTRI, and Aviptadil. The last is the emerging therapeutic areas, which include long acting rFactor IX.The company has established strategic alliances with Alnylam Pharmaceuticals, Inc.; Caprion Pharmaceuticals, Inc.; UCB S.A. Ltd. (2 collaborations); Elan Corporation, plc; Genentech, Inc. (2 collaborations); MONDObiotech; NsGene A/S; PDL BioPharma, Inc. (2 collaborations); Bayer Schering Pharma; Sunesis Pharmaceuticals, Inc. (2 collaborations); Vernalis, plc; and Zenyaku Kogyo Co. Ltd.The company's direct sales force and operations are located in Canada, Spain, Portugal, Australia, and throughout Europe. The company is also active in Switzerland, Netherlands, and Japan.

  • BIOGEN INC.

  • United States of America (US)
  • Tipo di azienda: Corporate
  • Impresa controllante: N/D
  • Amministratore Delegato (CEO): Dr. Stelios B Papadopoulos
  • Compenso Amministratore Delegato: 545.858,025
  • Sito web: www.biogenidec.com

Parametri finanziari

Numero di dipendenti

9,610
9,100
7,400
7,800

Fatturato 1

10
11
13
12

EBIT 1

3
4
7
5

EBITDA 1

4
4
7
6

1 numeri espressi in milioni

  • RepRisk indicator (ultimo mese):  23

Dialogo sociale

  • Transnational Corporate Agreement (TCA): N/D
  • Global Framework Agreement (GFA): N/D
  • Societas Europaea (SE): N/D
  • Bangladesh Accord: N/D

Comitati Aziendali Europei

  • CAE: N/D

Standard e certificazioni

  • Global Compact: N/D
  • CDP (Carbon Disclosure Project): N/D
  • Modern Slavery Statement: N/D
  • Transparency Index: N/D
  • SA8000 Social Accountability: N/D
  • Bilancio Integrato: N/D
  • ISO26000: N/D
  • Linee Guida Ocse: N/D
  • Social Development Goals (SDGs): N/D

Certificazione Global Reporting Initiative

  • Global Reporting Initiative standards: N/D
  • Global Reporting Initiative GRI G4: N/D

Altre dichiarative aziendali

  • Responsabilità sociale d'impresa:
    N/D
  • Accessibilità: N/D

Altre risorse

Policy

  • Policy sulla formazione: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro dove opera l'azienda: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro lungo filiera: N/D
  • Policy sulla diversità: N/D

Dichiarazioni universali

Dichiarazioni e trattati riconosciuti dal paese in cui l'azienda ha la sede legale

  • Dichiarazione universale dei Diritti Umani:
  • Convenzione europea dei diritti dell'uomo (CEDU):
  • Carta dei Diritti Fondamentali dei Lavoratori CDFL (Carta di Strasburgo 1989):
  • Carta dei diritti fondamentali dell'Unione Europea CDF UE (Carta di Nizza 2000):
  • Trattato sul funzionamento dell'Unione europea TFUE:
  • Sede legale in un Paese OCSE:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Direttive applicate alle sedi nella UE 27

  • D. 80/987/EEC: N/D
  • D. 89/391/EEC: N/D
  • D. 98/59/EC: N/D
  • D. 2000/43/EC: N/D
  • D. 2000/78/EC: N/D
  • D. 2001/23/EC: N/D
  • D. 2001/86/EC del Consiglio: N/D
  • D. 2002/14/EC: N/D
  • D. 2002/73/EC: N/D
  • D. 2003/72/EC del Consiglio: N/D
  • D. 2005/56/EC del PE e del Consiglio: N/D
  • D. 2009/38/EC: N/D
  • D. 2004/25/EC: N/D
  • D. 2011/35/EU: N/D

Presenza nei principali ranking

  • Global 100 Most Sustainable Corporations: N/D
  • Global CSR Rep Trak 100: N/D
  • BrandZ Top 100 Most Valuable US Brands: N/D
  • The Worlds Best Multinational Workplaces: N/D
  • The Gartner Supply Chain Top 25: N/D
  • The Worlds Most Innovative Companies: N/D
  • The Diversity Inc Top 50 Companies: N/D
  • Best Global Websites: N/D
  • Green Ranking Global Top 500: N/D
  • Green Ranking Global Top 100: N/D

Sindacati di riferimento